首页> The Lancet. Oncology> The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Richard S,Finn

第一单位： University of California Los Angeles, Los Angeles, CA, USA.

作者： Richard S,Finn ^[1] ; John P,Crown ^[2] ; Istvan,Lang ^[3] ; Katalin,Boer ^[4] ; Igor M,Bondarenko ^[5] ; Sergey O,Kulyk ^[6] ; Johannes,Ettl ^[7] ; Ravindranath,Patel ^[8] ; Tamas,Pinter ^[9] ; Marcus,Schmidt ^[10] ; Yaroslav,Shparyk ^[11] ; Anu R,Thummala ^[12] ; Nataliya L,Voytko ^[13] ; Camilla,Fowst ^[14] ; Xin,Huang ^[15] ; Sindy T,Kim ^[15] ; Sophia,Randolph ^[15] ; Dennis J,Slamon ^[16]

作者单位： University of California Los Angeles, Los Angeles, CA, USA. ^[1] Irish Cooperative Oncology Research Group, Dublin, Ireland. ^[2] Orszagos Onkologiai Intezet, Budapest, Hungary. ^[3] Szent Margit Korhaz, Onkologia, Budapest, Hungary. ^[4] Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital 4, Dnipropetrovsk, Ukraine. ^[5] Municipal Treatment and Prophylactic Institution, Donetsk, Ukraine. ^[6] Technical University of Munich, Munich, Germany. ^[7] Comprehensive Blood and Cancer Center, Bakersfield, CA, USA. ^[8] Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary. ^[9] University Hospital Mainz, Mainz, Germany. ^[10] Lviv State Oncologic Regional Treatment and Diagnostic Centre, Lviv, Ukraine. ^[11] Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA. ^[12] Kyiv City Clinical Oncology Centre, Kyiv, Ukraine. ^[13] Pfizer Oncology, Milan, Italy. ^[14] Pfizer Oncology, San Diego, CA, USA. ^[15] University of California Los Angeles, Los Angeles, CA, USA. Electronic address: dslamon@mednet.ucla.edu. ^[16]